A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Aldafermin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors NGM Biopharmaceuticals
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 04 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov
- 08 Jul 2013 Planned End Date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.